Shares of Natco Pharma Ltd were trading in the red and 1% lower on Wednesday, 20 August, despite the company announcing the launch of oral suspension tablets for the treatment of pulmonary arterial hypertension (PAH).

In an exchange filing, the business announced the launch of Bosentan tablets for oral suspension (TFOS), 32mg, a generic version of Actelion Pharmaceuticals US Inc.’s Tracleer. Lupin Ltd. is NATCO’s marketing partner for this product.

The company added that it is the first to register for this medicine and will have 180 days of generic drug exclusivity.

Bosentan tablets are used to treat pulmonary arterial hypertension (PAH) (WHO Group 1) in paediatric patients aged three years and older who have idiopathic or congenital PAH. They improve pulmonary vascular resistance (PVR), which is predicted to result in improved exercise capacity.

According to industry sales figures, the medicine is expected to generate $10 million in sales in the United States for the fiscal year ending June 2025.

Natco Pharma announced its first-quarter profits last week. In the June quarter, the company’s overall net profit fell to Rs 480 crore from Rs 668.5 crore the year before. Revenue fell 2.5% to Rs 1,329 crore, while EBITDA plummeted 32% to Rs 519 crore from Rs 764.9 crore the previous year. Its operating margins fell to 39% from 56.1% a year ago. 

At 3:10 pm, the shares of Natco Pharma were trading 0.33% lower at Rs 889.75 on NSE.

Feeling overwhelmed by the markets? Let Unicorn Signals be your guide. Our user-friendly app simplifies complex data and provides actionable trading signals. Download the app today and trade with confidence!